LeprosyNCT00138437
Molecular and Immunological Tools for Detection of Strain Diversity, Drug Resistance and Immunological Responses
An observational study of Leprosy, run by Colorado State University at 2 sites in Colombia.
Trial summary
The purpose of this study is to determine what factors contribute to the continued incidence of leprosy in Colombia. Study participants will include volunteering and consenting individuals, older than 4 years of age, representing three study groups: 1. healthy persons with no known contact with leprosy patients 2. Read more about this study
- Who is it for?
- Ages 18 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Leprosy
- How many people
- 1,554 participants
- Where
- 2 sitesColombia
- Study dates
- Apr 2006to Apr 2013
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Study participants for prospective sample collections will include volunteering and consenting individuals older than 18 years of age, representing three study groups
Who may be able to join
- All leprosy patients (Group1), their household contacts (Group 2) and healthy persons with no known contacts with leprosy patients (Group 3), between the ages of 18 and 70 years willing to participate in this study.
Who cannot join
- Patients unwilling to participate or unable to give informed consent will be excluded from the study.
- Pregnant women will be excluded.
- Exclusion criteria for objective A.5 are one or more of the following conditions:
- Chronic illnesses such as cancer
- Diabetes
- Hepatitis
Show all 10Show fewer
- HIV
- Tuberculosis
- Undergoing corticosteroid therapy
- Current or previous history of immunosuppressive therapy as assessed from medical records and interviews with a physician.
Trial locations and contacts
2 sites in 1 country.
Colombia2 sites
Impresa Socail del Estado Sanatorio Agua de Dios
Agua de Dios
Instituto Colombiano de Medicina Tropical-CES
Sabaneta
About this study
Official title: Molecular Epidemiology of Leprosy in Colombia
The purpose of this study is to determine what factors contribute to the continued incidence of leprosy in Colombia. Study participants will include volunteering and consenting individuals, older than 4 years of age, representing three study groups:
- healthy persons with no known contact with leprosy patients
- patients reporting at Instituto Colombiano de Medicina Tropical-CES and Impresa Social del Estado Sanatorio Agua de Dios with a new diagnosis of leprosy or relapse of leprosy
- household contacts of leprosy patients described in group 2. Blood, nasal swabs, slit skin smears, and biopsies will be taken from the volunteers to learn the strains of leprosy-causing bacteria in the area, the immune responses (body's response to disease) in local residents against the bacteria, and the pattern of leprosy transmission. Individuals will participate in this study for 1-10 days, and the study will last for 3 years.
Read the detailed description
The overall objectives of this study are to understand the factors leading to continued incidence of leprosy in Colombia by novel molecular methodologies using a combination of retrospective and prospective sampling approaches using three study groups. Specific objectives are: (1) strain typing of M. leprae isolates obtained from newly diagnosed leprosy patients and household contacts (HHCs) in Colombia to identify clusters and transmission patterns when combined with conventional epidemiological criteria; (2) to determine the viability of M. leprae by mRNA detection in specimens collected from new leprosy patients and HHCs; (3) to identify and determine the extent of mutations conferring resistance in past and circulating M. leprae isolates from leprosy patients to two Multidrug therapy (MDT) drugs; dapsone and rifampicin; (4) to detect chains of transmission in endemic populations by a retrospective analyses of isolates in sample banks when combined with strain typing information from new cases and conventional epidemiological criteria; and (5) to detect, compare, and delineate immune response profiles to M. leprae antigens as biomarkers for early detection of leprosy and prediction of clinical outcome (susceptible, infected, and resistant individuals) among three study groups. Study participants for prospective sample collections will include volunteering and consenting individuals older than 4 years of age, representing three study groups: (1) healthy persons with no known contacts with leprosy patients, (2) patients reporting at Instituto Colombiano de Medicina Tropical-CES (ICMT-CES) and Impresa Social del Estado Sanatorio Agua de Dios for the diagnosis of leprosy and/or relapse of leprosy, and (3) household contacts (HHC) of leprosy patients reporting at Instituto Colombiano de Medicina Tropical-CES (ICMT-CES) and Impresa Social del Estado Sanatorio Agua de Dios. Blood, nasal swabs, slit skin smears and biopsies will be obtained prospectively from individuals greater than 4 years of age representing three study groups: newly diagnosed and relapse leprosy patients, their household contacts; and healthy persons with no known contacts with leprosy patients. Retrospective archived samples from past and present leprosy patients will be included when available. DNA and RNA based methodologies will be developed and applied to obtain data necessary for substantiation of a number of factors implicated in transmission of leprosy in Colombia. Nucleic acid based molecular methods like Multiple Locus Variable number of tandem repeat Analysis (MLVA) and Single Nucleotide Polymorphisms (SNPs) will be performed for strain typing M. leprae, in combination with epidemiological information to delineate the distribution of types of the organism in various regions of Colombia. Other DNA markers such as mutations causing drug resistance will also be collected from the M. leprae containing specimens. Due to the lack of methods to cultivate M. leprae, viability of the organism in newly collected biological samples will be tested by mRNA detection. A database will be generated which will include M. leprae genotypes, patient history (clinical and demographic) for comprehensive epidemiological analyses to monitor prevailing M. leprae population structures reflective of short and long range dissemination; and correlations between disease type and genotype; to track evolutionary and transmission patterns. Profiling of host immunological responses during infection with M. leprae will be done by detection of a panel of cytokines at the level of mRNA and/or protein, and detection of antibodies against M. leprae antigens in leprosy patients, their household contacts and healthy individuals with no known history or contacts with leprosy patients.
- Conditions
- Leprosy
- Keywords
- leprosy, Colombia
- Medical subject headings
- Leprosy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Leprosy Patients (Group 1) | All leprosy patients | |
| Household Contacts (Group 2) | Household contacts with known contact with leprosy patients | |
| Healthy Individuals (Group 3) | Healthy persons with no known contact with leprosy patients |
What is being measured
The primary outcome is the main question the study is designed to answer.
Strain typing: identification of genotypes
Measured: Dec, 2010
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Aug 2005 (estimated)
- Study startApr 2006
- Primary completionApr 2013
- Study completionApr 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for LeprosyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 1,554 participants (actual)
Sponsor and investigators
- Lead sponsor
- Colorado State University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Varalakshmi Vissa, PhD, Principal investigator, Colorado State UniversityNora Cardona-Castro, MD, MSc, Principal investigator, Instituto Colombiano de Medicina Tropical - Universidad CES
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00138437
- Sponsor's protocol ID
- 09-817H
- Status last verified
- Nov 2014
- First submitted
- 26 Aug 2005
- Last updated
- 7 Nov 2014
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Nov 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Molecular Epidemiology of Leprosy in Colombia
- ClinicalTrials.gov ID
- NCT00138437
- Acronym / sponsor ID
- 09-817H
- Conditions
- Leprosy
- Keywords
- leprosy, Colombia
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,554 participants (actual)
- Lead sponsor
- Colorado State UniversityUniversity, hospital or other
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID)
- Study start
- Apr 2006
- Primary completion
- Apr 2013 (actual)
- Study completion
- Apr 2013 (actual)
- First posted
- 30 Aug 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine what factors contribute to the continued incidence of leprosy in Colombia. Study participants will include volunteering and consenting individuals, older than 4 years of age, representing three study groups:
- healthy persons with no known contact with leprosy patients
- patients reporting at Instituto Colombiano de Medicina Tropical-CES and Impresa Social del Estado Sanatorio Agua de Dios with a new diagnosis of leprosy or relapse of leprosy
- household contacts of leprosy patients described in group 2. Blood, nasal swabs, slit skin smears, and biopsies will be taken from the volunteers to learn the strains of leprosy-causing bacteria in the area, the immune responses (body's response to disease) in local residents against the bacteria, and the pattern of leprosy transmission. Individuals will participate in this study for 1-10 days, and the study will last for 3 years.
Detailed description
The overall objectives of this study are to understand the factors leading to continued incidence of leprosy in Colombia by novel molecular methodologies using a combination of retrospective and prospective sampling approaches using three study groups. Specific objectives are: (1) strain typing of M. leprae isolates obtained from newly diagnosed leprosy patients and household contacts (HHCs) in Colombia to identify clusters and transmission patterns when combined with conventional epidemiological criteria; (2) to determine the viability of M. leprae by mRNA detection in specimens collected from new leprosy patients and HHCs; (3) to identify and determine the extent of mutations conferring resistance in past and circulating M. leprae isolates from leprosy patients to two Multidrug therapy (MDT) drugs; dapsone and rifampicin; (4) to detect chains of transmission in endemic populations by a retrospective analyses of isolates in sample banks when combined with strain typing information from new cases and conventional epidemiological criteria; and (5) to detect, compare, and delineate immune response profiles to M. leprae antigens as biomarkers for early detection of leprosy and prediction of clinical outcome (susceptible, infected, and resistant individuals) among three study groups. Study participants for prospective sample collections will include volunteering and consenting individuals older than 4 years of age, representing three study groups: (1) healthy persons with no known contacts with leprosy patients, (2) patients reporting at Instituto Colombiano de Medicina Tropical-CES (ICMT-CES) and Impresa Social del Estado Sanatorio Agua de Dios for the diagnosis of leprosy and/or relapse of leprosy, and (3) household contacts (HHC) of leprosy patients reporting at Instituto Colombiano de Medicina Tropical-CES (ICMT-CES) and Impresa Social del Estado Sanatorio Agua de Dios. Blood, nasal swabs, slit skin smears and biopsies will be obtained prospectively from individuals greater than 4 years of age representing three study groups: newly diagnosed and relapse leprosy patients, their household contacts; and healthy persons with no known contacts with leprosy patients. Retrospective archived samples from past and present leprosy patients will be included when available. DNA and RNA based methodologies will be developed and applied to obtain data necessary for substantiation of a number of factors implicated in transmission of leprosy in Colombia. Nucleic acid based molecular methods like Multiple Locus Variable number of tandem repeat Analysis (MLVA) and Single Nucleotide Polymorphisms (SNPs) will be performed for strain typing M. leprae, in combination with epidemiological information to delineate the distribution of types of the organism in various regions of Colombia. Other DNA markers such as mutations causing drug resistance will also be collected from the M. leprae containing specimens. Due to the lack of methods to cultivate M. leprae, viability of the organism in newly collected biological samples will be tested by mRNA detection. A database will be generated which will include M. leprae genotypes, patient history (clinical and demographic) for comprehensive epidemiological analyses to monitor prevailing M. leprae population structures reflective of short and long range dissemination; and correlations between disease type and genotype; to track evolutionary and transmission patterns. Profiling of host immunological responses during infection with M. leprae will be done by detection of a panel of cytokines at the level of mRNA and/or protein, and detection of antibodies against M. leprae antigens in leprosy patients, their household contacts and healthy individuals with no known history or contacts with leprosy patients.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Leprosy Patients (Group 1) | – | –All leprosy patients |
| Household Contacts (Group 2) | – | –Household contacts with known contact with leprosy patients |
| Healthy Individuals (Group 3) | – | –Healthy persons with no known contact with leprosy patients |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Study participants for prospective sample collections will include volunteering and consenting individuals older than 18 years of age, representing three study groups
Key inclusion criteria (1 listed)
- All leprosy patients (Group1), their household contacts (Group 2) and healthy persons with no known contacts with leprosy patients (Group 3), between the ages of 18 and 70 years willing to participate in this study.
Key exclusion criteria (10 listed)
- Patients unwilling to participate or unable to give informed consent will be excluded from the study.
- Pregnant women will be excluded.
- Chronic illnesses such as cancer
- Diabetes
- Hepatitis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Strain typing: identification of genotypes
Time frame: Dec, 2010
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Nov 2014.
Related trials for Leprosy
Not yet recruitingPhase 2
Telacebec in Adults With Multibacillary Leprosy (TEBULA Leprosy Trial)
Leprosy, Multibacillary
RecruitingPhase 2
Efficacy and Safety Study of Dovramilast in People With Leprosy Type 2 Reaction
Erythema Nodosum Leprosum
RecruitingObservational study
Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
Atopic Dermatitis, Psoriasis
RecruitingPhase 3
Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy
Leprosy
Recruiting
Accuracy of the Polymerase Chain Reaction of Ulnar Perineural Subcutaneous Aspirate Guided by Ultrasound for the Diagnosis and Monitoring of Leprosy Cure
Leprosy, Leprosy Neuropathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Varalakshmi Vissa, PhD principal investigator
Colorado State University
Nora Cardona-Castro, MD, MSc principal investigator
Instituto Colombiano de Medicina Tropical - Universidad CES
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Leprosy, run by Colorado State University at 2 sites in Colombia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Nov 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Colombia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Strain typing: identification of genotypes (time frame: Dec, 2010). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Nov 2014.